JP2022533958A5 - - Google Patents
Info
- Publication number
- JP2022533958A5 JP2022533958A5 JP2021568229A JP2021568229A JP2022533958A5 JP 2022533958 A5 JP2022533958 A5 JP 2022533958A5 JP 2021568229 A JP2021568229 A JP 2021568229A JP 2021568229 A JP2021568229 A JP 2021568229A JP 2022533958 A5 JP2022533958 A5 JP 2022533958A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvate
- acceptable salt
- deuterium
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847519P | 2019-05-14 | 2019-05-14 | |
| US62/847,519 | 2019-05-14 | ||
| PCT/US2020/032725 WO2020232156A1 (en) | 2019-05-14 | 2020-05-13 | Compound for treating gout or hyperuricemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533958A JP2022533958A (ja) | 2022-07-27 |
| JP2022533958A5 true JP2022533958A5 (enExample) | 2023-05-15 |
| JP7656548B2 JP7656548B2 (ja) | 2025-04-03 |
Family
ID=73288915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568229A Active JP7656548B2 (ja) | 2019-05-14 | 2020-05-13 | 痛風または高尿酸血症を処置するための化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220242841A1 (enExample) |
| EP (1) | EP3968989A4 (enExample) |
| JP (1) | JP7656548B2 (enExample) |
| KR (1) | KR20220016105A (enExample) |
| CN (1) | CN113874014A (enExample) |
| AU (2) | AU2020274165A1 (enExample) |
| BR (1) | BR112021022843A2 (enExample) |
| CA (1) | CA3140412A1 (enExample) |
| IL (1) | IL288034B1 (enExample) |
| MA (1) | MA55973A (enExample) |
| MX (1) | MX2021013980A (enExample) |
| SG (1) | SG11202112562XA (enExample) |
| TW (1) | TW202108561A (enExample) |
| WO (1) | WO2020232156A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3121624A1 (en) | 2018-12-06 | 2020-06-11 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing gout or hyperuricemia |
| US12145917B2 (en) | 2018-12-06 | 2024-11-19 | Arthrosi Therapeutics, Inc. | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| WO2021252630A1 (en) * | 2020-06-10 | 2021-12-16 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing chronic kidney disease |
| KR20230050232A (ko) * | 2021-10-07 | 2023-04-14 | 주식회사 이노보테라퓨틱스 | 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물 |
| US20250066316A1 (en) * | 2021-12-02 | 2025-02-27 | Arthrosi Therapeutics, Inc. | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| CN118974028A (zh) * | 2021-12-30 | 2024-11-15 | 广州瑞安博医药科技有限公司 | 用于治疗痛风或高尿酸血症的化合物的制备 |
| US20250242050A1 (en) | 2024-01-31 | 2025-07-31 | The Industry & Academic Cooperation In Chungnam National University (Iac) | Composition for treating gout containing cyclodextrin-conjugated polymer nano-drug and method for treating gout |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9962362B2 (en) * | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| CN113214198B (zh) * | 2016-07-18 | 2022-12-23 | 广州瑞安博医药科技有限公司 | 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法 |
| WO2019195118A1 (en) * | 2018-04-03 | 2019-10-10 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
| US12145917B2 (en) * | 2018-12-06 | 2024-11-19 | Arthrosi Therapeutics, Inc. | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
-
2020
- 2020-05-13 EP EP20804806.6A patent/EP3968989A4/en active Pending
- 2020-05-13 KR KR1020217041035A patent/KR20220016105A/ko active Pending
- 2020-05-13 TW TW109115899A patent/TW202108561A/zh unknown
- 2020-05-13 AU AU2020274165A patent/AU2020274165A1/en not_active Abandoned
- 2020-05-13 MX MX2021013980A patent/MX2021013980A/es unknown
- 2020-05-13 CA CA3140412A patent/CA3140412A1/en active Pending
- 2020-05-13 CN CN202080035809.1A patent/CN113874014A/zh active Pending
- 2020-05-13 WO PCT/US2020/032725 patent/WO2020232156A1/en not_active Ceased
- 2020-05-13 SG SG11202112562XA patent/SG11202112562XA/en unknown
- 2020-05-13 MA MA055973A patent/MA55973A/fr unknown
- 2020-05-13 JP JP2021568229A patent/JP7656548B2/ja active Active
- 2020-05-13 US US17/610,673 patent/US20220242841A1/en active Pending
- 2020-05-13 IL IL288034A patent/IL288034B1/en unknown
- 2020-05-13 BR BR112021022843A patent/BR112021022843A2/pt unknown
-
2026
- 2026-03-23 AU AU2026202224A patent/AU2026202224A1/en active Pending